Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes
AE El-Sisi, SK Hegazy, SS Metwally… - Therapeutic …, 2011 - journals.sagepub.com
Therapeutic advances in endocrinology and metabolism, 2011•journals.sagepub.com
Objective: This study investigated the possibility that genetic factors, such as polymorphism
of K inward rectifier subunit (Kir6. 2), E23K, and Arg972 polymorphism of insulin receptor
substrate-1 (IRS-1), may predispose patients to sulfonylurea failure. Methods: A total of 100
unrelated Egyptian patients with type 2 diabetes were recruited. They were divided into two
equal groups: group I consisted of patients with secondary failure to sulfonylurea
(hemoglobin A1c≥ 8% despite sulfonylurea therapy) while group II consisted of patients …
of K inward rectifier subunit (Kir6. 2), E23K, and Arg972 polymorphism of insulin receptor
substrate-1 (IRS-1), may predispose patients to sulfonylurea failure. Methods: A total of 100
unrelated Egyptian patients with type 2 diabetes were recruited. They were divided into two
equal groups: group I consisted of patients with secondary failure to sulfonylurea
(hemoglobin A1c≥ 8% despite sulfonylurea therapy) while group II consisted of patients …
Objective: This study investigated the possibility that genetic factors, such as polymorphism of K inward rectifier subunit (Kir6.2), E23K, and Arg972 polymorphism of insulin receptor substrate-1 (IRS-1), may predispose patients to sulfonylurea failure.
Methods: A total of 100 unrelated Egyptian patients with type 2 diabetes were recruited. They were divided into two equal groups: group I consisted of patients with secondary failure to sulfonylurea (hemoglobin A1c ≥ 8% despite sulfonylurea therapy) while group II consisted of patients whose condition was controlled with oral therapy.
Results: Of all the patients, 45% and 14% were carriers of the K allele and Arg972 variants respectively. The frequency of the K allele was 34% among patients with diabetes that was controlled with oral therapy and 56% among patients with secondary failure to sulfonylurea. The frequency of the Arg972 IRS-1 variant was 6% among patients with diabetes controlled with oral therapy and 22% among patients with secondary failure.
Conclusion: The E23K variant of the Kir6.2 gene and Arg972 IRS-1 variants are associated with increased risk for secondary failure to sulfonylurea.
Sage Journals以上显示的是最相近的搜索结果。 查看全部搜索结果